Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growth

Laurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by robust growth in its CDMO business and affordable medicines portfolio. The company also reported margin expansion, reaffirmed its capex plans, and continued to attract higher institutional interest, boosting investor sentiment.